Rhythm Pharmaceuticals, Inc.
RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) dā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$97.61
Price+1.17%
$1.13
1Y
Price
Market Cap
$6.483b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-537.1%
EBITDA Margin-544.4%
Net Profit Margin-310.9%
Free Cash Flow MarginRevenue
$156.287m
+18.7%
1y CAGR+298.6%
3y CAGR+223.9%
5y CAGREarnings
-$183.063m
-48.3%
1y CAGR-72.8%
3y CAGR-42.6%
5y CAGREPS
-$2.99
-44.7%
1y CAGR-64.0%
3y CAGR-34.6%
5y CAGRBook Value
$133.583m
$372.733m
Assets$239.150m
Liabilities$4.191m
DebtDebt to Assets
1.1%
-0.4x
Debt to EBITDAFree Cash Flow
-$67.724m
-33.1%
1y CAGR-9.0%
3y CAGR-12.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company